Español
Questions About Cancer? 1-800-4-CANCER
  • Email

Clinical Trials Search Results

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 151 for your search:
Cancer Type/Condition:  aggressive, noncontiguous stage II adult non-Hodgkin lymphoma
Stage/Subtype:  aggressive, noncontiguous stage II adult non-Hodgkin lymphoma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Plerixafor-UF01, NCT01339572

2.

Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000433265, CALGB-50303, ECOG-50303, NCI-05-C-0252, NCT00118209

3.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 110918, NCT01077518

4.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, P30CA015704, NCT01231412

5.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IELSG37, NCT01599559

6.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 116428, 2012-003438-18, NCT01767467

7.

Phase: Phase III
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: CB-AB006, 2012-0166, NCT01854567

8.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR102118, PCI-32765DBL3001, U1111-1139-6222, 2013-000959-40, NCT01855750

9.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-NHL-008, NCT01996865

10.

Phase: Phase III
Type: Treatment
Status: Active
Age: 2 to 30
Sponsor: NCI
Protocol IDs: NCI-2014-00712, AALL1231, U10CA098543, U10CA180886, NCT02112916

11.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IPI-145-08, 2013-002406-31, NCT02204982

12.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B3281006, 2014-000132-41, NCT02213263

13.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: 95-024, P30CA008748, MSKCC-95024, NCI-V95-0685, NCT00002663

14.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: 8713-HIMSUM, NCT00058825

15.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: CDR0000447204, P30CA016058, OHSU-HEM-05011-L, OHSU-210, NCT00245037

16.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: MC078E, P30CA015083, RV-NHL-PI-0325, 07-007992, NCI-2009-01196, MAYO-MC078E, CELGENE-RV-NHL-PI-0325, NCT00670358

17.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Any age
Sponsor: NCI, Other
Protocol IDs: 2230.00, NCI-2010-00106, P30CA015704, P01CA078902, FHCRC-2230.00, IR-6771, NCT00789776

18.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 1001010838, NCT01147393

19.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: PSOC 2502, NCI-2010-00907, P30CA015704, NCT01165112

20.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02508, AMC #75, CDR0000683379, AMC-075, U01CA121947, NCT01193842

21.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2011-001, NCT01416428

22.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PSHCI 10-011, NCT01439750

23.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 55
Sponsor: Pharmaceutical / Industry
Protocol IDs: CHSC835X2201, NCT01474681

24.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 11411, NCT01575860

25.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2011-203, NCT01609816
1     
New Search